Back to Search Start Over

Health-Related Quality of Life with Gilteritinib Versus Placebo Post-Transplant Maintenance for FLT3-ITD+ Acute Myeloid Leukemia (AML): A Quality of Life Analysis from BMT CTN 1506

Authors :
Hamilton, Betty K.
Levis, Mark J.
Pandya, Bhavik J
Elsouda, Dina
Logan, Brent
Chen, Dr. Yi-Bin
Hamadani, Mehdi
Ueda, Masumi
Perl, Alexander E.
Singh, Anurag K.
Soiffer, Robert J.
Litzow, Mark R.
Ustun, Celalettin
Rosales, Matt
Ivanescu, Cristina
Cella, David
Hasabou, Nahla
Corredoira, Laura
Pestana, Carolina
Horowitz, Mary M.
Source :
Transplantation and Cellular Therapy; February 2024, Vol. 30 Issue: 2, Number 2 Supplement 1 pS44-S45, 2p
Publication Year :
2024

Abstract

The Blood and Marrow Transplant Clinical Trials Network study 1506 (NCT02997202) was a multi-center phase III randomized trial comparing gilteritinib versus placebo after allogeneic hematopoietic cell transplantation (HCT) in patients with FLT3-ITD-positive AML. The primary analysis comparing relapse-free survival (RFS) did not reach statistical significance, with higher treatment-emergent adverse events (TEAE) with gilteritinib. In patients with detectable FLT3-ITDmeasurable residual disease (MRD) peri-HCT, gilteritinib was associated with significantly longer RFS, demonstrating efficacy of MRD monitoring and intervention with FLT3 inhibition in MRD positive patients. The impact of gilteritinib maintenance on health-related quality of life (HRQoL) is not known; and the aim of this prespecified exploratory analysis is to describe the effect of gilteritinib versus placebo on HRQoL.

Details

Language :
English
ISSN :
26666375 and 26666367
Volume :
30
Issue :
2, Number 2 Supplement 1
Database :
Supplemental Index
Journal :
Transplantation and Cellular Therapy
Publication Type :
Periodical
Accession number :
ejs65462632
Full Text :
https://doi.org/10.1016/j.jtct.2023.12.077